Anti-interferon-α neutralizing antibody induced telaprevir resistance under the interferon-α plus telaprevir treatment in vitro

Kuga, Chisa; Enomoto, Hirayuki; Aizawa, Nobuhiro; Takashima, Tomoyuki; Ikeda, Naoto; Ishii, Akio; Sakai, Yoshiyuki; Iwata, Yoshinori; Tanaka, Hironori; Saito, Masaki; Iijma, Hiroko; Nishiguchi, Shuhei

doi:10.1016/j.bbrc.2014.10.111

Cited by 2 publications

(1 citation statement)

References 36 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In 2010, Halfon et al [35] measured anti-IFN-α NAbs with a plus RBV therapy often show a poor response to robust triple therapy (Peg-IFN-α plus RBV plus a DAA), the factors associated with the response to IFN treatment were also suggested to have an impact on the new DAAcontaining therapy. We recently used the HCV-replicon system with genotype 1b to assess the potential role of anti-IFN-α NAb in the response to DAA-containing triple therapy [37] . Although telaprevir (TVR) monotherapy rapidly reduced the HCV-RNA level in vitro, the HCV-RNA level was increased again with the emergence of TVR-resistant viruses.…”

Section: The Role Of Anti-ifn-α Neutralizing Antibodies In Ifn-α Treamentioning

confidence: 99%

Factors associated with the response to interferon-based antiviral therapies for chronic hepatitis C

Enomoto

Nishiguchi

2015

WJH

Self Cite

View full text Add to dashboard Cite

Hepatitis C virus (HCV) infection is a major health concern worldwide. Interferon-α (IFN-α) therapy has been the main antiviral treatment for more than 20 years. Because of its established antitumor effects, IFNbased treatments for chronic HCV infection still have a clinical impact, particularly for patients with high risk conditions of developing hepatocellular carcinoma, such as older age and advanced liver fibrosis. As a result of exhaustive research, several viral factors, including NS5A amino acid mutations such as the IFN sensitivitydetermining region and the IFN/ribavirin resistancedetermining region, and mutations of amino acids in the core protein region (core 70 and 91) were shown to be associated with the response to IFN-α treatment. In addition, among the host factors related to the response to IFN-α treatment, polymorphisms of the interleukin-28B gene were identified to be the most important factor. In this article, we review the factors associated with the efficacy of IFN-α treatment for chronic HCV infection. In addition, our recent findings regarding the possible involvement of anti-IFN-α neutralizing antibodies in a non-response to pegylated-IFN-α treatment are also described. Core tip: Interferon-α (IFN-α) therapy has been playing a central role in anti-hepatitis C virus (HCV) strategies, and several viral and host factors related to the treatment efficacy have been identified. After the development of pegylated-IFN-α (Peg-IFN-α), the clinical impact of anti-IFN-α neutralizing antibodies in the treatment for HCV infection has not been sufficiently addressed. We recently found that anti-IFN-α neutralizing antibodies were associated with a non-response to Peg-IFN-α treatment. Our findings provide important information for the treatment of chronic hepatitis C in the clinical setting. MINIREVIEWSSubmit a

show abstract

Section: The Role Of Anti-ifn-α Neutralizing Antibodies In Ifn-α Treamentioning

confidence: 99%

Factors associated with the response to interferon-based antiviral therapies for chronic hepatitis C

Enomoto

Nishiguchi

2015

WJH

Self Cite

View full text Add to dashboard Cite

show abstract

Natural interferon-beta treatment for patients with chronic hepatitis C in Japan

Sasaki¹,

Nakamoto²,

Haga³

et al. 2015

WJH

View full text Add to dashboard Cite

Anti-interferon-α neutralizing antibody induced telaprevir resistance under the interferon-α plus telaprevir treatment in vitro

Cited by 2 publications

References 36 publications

Factors associated with the response to interferon-based antiviral therapies for chronic hepatitis C

Factors associated with the response to interferon-based antiviral therapies for chronic hepatitis C

Natural interferon-beta treatment for patients with chronic hepatitis C in Japan

Contact Info

Product

Resources

About